Hyaluronan (HA) is widely used in the treatment of osteoartritis (OA) while its mechanisms of action is poorly understood. Since chondrocyte apoptosis seems involved in the pathogenesis of OA we investigated the in vitro effect of a 500-730 kd fraction of therapeutic hyaluronan (HA) on anti-Fas induced apoptosis of chondrocytes from OA patients and its mechanism of action analyzing the role of the two HA receptors, CD44 and CD54 (ICAM-1).
Hyaluronan (HA) is widely used in the treatment of osteoartritis (OA) while its mechanisms of action is poorly understood. Since chondrocyte apoptosis seems involved in the pathogenesis of OA we investigated the in vitro effect of a 500-730 kd fraction of therapeutic hyaluronan (HA) on anti-Fas induced apoptosis of chondrocytes from OA patients and its mechanism of action analyzing the role of the two HA receptors, CD44 and CD54 (ICAM-1).
Methods: Chondrocytes isolated from human OA knee were cultured and the effect of HA was evaluated both on spontaneous and anti-Fas induced apoptosis. Apoptosis was analyzed by JAM test (for quantitative analysis of fragmented DNA), cell death detection immunoassay (for quantitative analysis of oligonucleosome), TUNEL assay and electron microscopy. Blocking experiments with anti-CD44 and anti-CD54 alone or in combination were performed to investigate the HA action mechanism.
Results: Both quantitative tests demonstrated that anti-Fas significantly induced apoptosis of isolated OA chondrocytes. HA at 1000 mg/ml significantly reduced anti-Fas induced apoptosis of chondrocytes, but did not affect spontaneous chondrocyte apoptosis. These data were also confirmed by TUNEL staining and by electron microscopy. Anti-apoptotic effects of HA on antiFAS induced chondrocyte apoptosis were significantly decreased by both anti-CD44 (67 ± 14% of inhibition) and CD54 (39 ± 30% of inhibition). The mixture of the two antibodies had an addictive effect, since the rate of inhibition increased to 87 ± 13%.
Conclusions:
The anti-apoptotic effect of HA mediated by its specific receptors can account for its therapeutic action in OA. Endothelin-1 (ET-1) is known as a powerful vasoconstritor. This peptide is also found expressed in various tissues and cells and is suggested to play a role in many disorders including joint diseases.
Method: This study was designed to determine the El--1 involvement in human osteoarthritis (OA) pathophysiology. To this end, we first evaluated its presence in cartilage and synovial membrane using immunohistochemistry, and further investigated whether ET-I possessed catabolic properties on cartilage. OA cartilage was incubated in the absence or presence of increasing concentrations of ET-I, and the levels of metalloproteases (MMP), nitric oxide (NO), cyclooxygenase-2 (COX2) and apoptosis determined.
Results: Data showed that ET-1 is synthesized in both synovial membrane and cartilage. In cartilage, ET-1 production was preferentially located in the superficial and upper intermediate layers of the tissue. The number of chondrocytes that specifically stained for ET-1 in normal cartilage was very low (7.3+2.4%), and $9 significantly increased (28.1+8.8%, p<0.001)in OA. Moreover, in this pathological tissue, ET-1 was immunocolocalized with the proinflammatory cytokine IL-II3. As in cartilage, ET-1 was also found at low levels in normal synovial membrane and dramatically elevated in OA. In this tissue, ET-I specific immunostaining was found in the synovial lining cells as well as in the mononuclear cells. ET-1 demonstrated a selective effect on MMP production. It significantly stimulated MMP-I (control, 6.5±2.4; ET-I (10 nM), 9.5+2.8 pg/100 mg tissue, p<0.O08) and MMP-13 (control, 36.4±11.7; ET-1 (10 nM), 67.6±23.8 pg/100 mg tissue, p<0.007) but not MMP-3. This peptide also increased NO and COX-2 levels but had no effect on chondrocyte apoptosis.
Conclusion:
This study demonstrated, for the first time, the presence of ET-1 in human articular tissues with marked increase levels in OA cartilage and synovial membrane. We further demonstrated that ET-1 had a catabolic, but selective, role in OA cartilage. Studies exploring the ET-1 metabolic pathways involved in the cartilage catabolic processes are currently underway in our laboratory.
PP25

DIFFERENTIAL REGULATION OF CYTOKINE-ACTIVATED HUMAN SYNOVIAL FIBROBLAST COLLAGENASE-1 (MMP-1) GENE EXPRESSION BY PROSTAGLANDINS OF THE E AND J SERIES; ROLE OF AP-I AND C/EBP TRANSCRIPTION FACTORS
QW He, Y He, W Faour, JA Di Battista
Unite de recherche en arthrose, HSpital Notre-Dame du CHUM, Montreal (QC), Canada
We recently showed that production of MMP-1 is under the control of endogenously-produced arachidonic acid metabolites in human OA-affected synovial membranes. Our objective was to characterize the signaling pathways that mediate prostaglandin E 2 and J2 (PGE 2 and 15-deoxy-PGJ2) inhibition of basal and IL-113 activated collagenase-1 (MMP-1) gene expression in human OA-affected synovial membrane-derived synoviocytes (HSF). Interleukin-lb and phorbol ester (PMA) activated MMP-1 expression and synthesis were both inhibited by PGE 2 (IC50 = 30± 5 nmot/L) and 15-deoxy-PGJ 2 (IC50 4.5 ± 0.9 pmol/L) in a dosedependent fashion as judged by Northern (mRNA) and EL1SA (protein) analysis. NS-398, a preferential COX-2 inhibitor, stimulated basal and PMA/IL-I~ induced MMP-1 expression. ILl 13/PMA induction of MMP-1 promoter activity in HSF is dependent, in part, on the proximal (-66 bp) AP-I activation as judged by transient transfection analysis using wild-type and mutant promoter constructs in HSE PGE 2 stimulated while 15-deoxy-PGJ 2 inhibited IL-113/PMA induction of AP-1 dependent MMP-1 promoter activity in HSE Northern and gel-shift analysis of potential AP-1 dimers revealed that IL-I~/PMA stimulated the transient expression of c-jun, junD, and c-fos expression while PGE 2 activated the expression of c-los, fosB, ]unD and junD but strongly inhibited c-jun expression either alone or in the presence of ILl 13/PMA. 15 deoxy PGJ 2 potently inhibited c-fos, c-jun, and lunD.
Gel shift analysis detected MMP-1-AP-1 response element binding in control and IL-113/PMA-induced cells which was inhibited by 15 deoxy PGJ 2 but not PGE 2. PGE 2 inhibited c/EBP-dependent activation of the MMP-1 promoter in a specific time frame that coincided with an increase in ERKI/2 and SAPK2A/p38ct signaling pathways; the effect of PGE 2 depended on an intact distal c/EBP site in the human MMP-I promoter. Both prostanoids have no effect of MMP-1 mRNA half-life.
We conclude that 15 deoxy PGJ 2 inhibits cytokine-induced MMP-1 gene expression by blocking the synthesis of transcriptionally active AP-1 complexes while PGE 2 functions at a distal c/EBP enhancer site by blocking basal and IL-II3 induced c/EBP. This study describes a new auto-regulatory signaling paradigm in which membrane phospholipid-derived eicosanoids control cytokine target genes.
